Cell cycle and molecular targets: CDK inhibition

被引：5

作者：

Carassou, Philippe ^{[2
]}

Meijer, Laurent ^{[3
]}

Le Moulec, Sylvestre ^{[4
]}

Aoun, Jean ^{[2
]}

Bengrine-Lefevre, Leila ^{[1
]}

机构：

[1] Hop St Antoine, F-75571 Paris 12, France

[2] HIA Legouest, Serv Med Interne, F-57077 Metz 3, France

[3] CNRS, Grp Cycle Cellulaire, Biol Stn, F-29682 Roscoff, France

[4] HIA Val de Grace, F-75230 Paris 05, France

来源：

BULLETIN DU CANCER | 2012年 / 99卷 / 02期

关键词：

cell cycle; cyclin-dependent kinases; roscovitine; indirubin; meriolin; antitumor activity; PROTEIN-KINASE INHIBITORS; INDOLE-3-CARBINOL; MEDICINE; SURVIVAL; GROWTH; ROLES; DEATH; MCL-1; P27;

D O I：

10.1684/bdc.2011.1383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Protein phosphorylation is a fundamental post-translational modification. It regulates a large number of critical cellular processes (differentiation, division, proliferation, apoptosis). Cell division is a process including a series of phases by which a parent cell divides into two daughter cells. The cells enter these stages then progress within the cell division under an accurate control by many proteins. These proteins are activated by phosphorylation. Cyclin-dependent kinases are responsible for this phosphorylation and therefore represent potential therapeutic targets especially in oncology.

引用

收藏

页码：163 / 171

页数：9

相关论文

共 46 条

[1]

Molecular targets and anticancer potential of indole-3-carbinol and its derivatives [J].

Aggarwal, BB ;

Ichikawa, H .

CELL CYCLE, 2005, 4 (09) :1201-1215

[2]

Cdc2-cyclin E complexes regulate the G1/S phase transition [J].

Aleem, E ;

Kiyokawa, H ;

Kaldis, P .

NATURE CELL BIOLOGY, 2005, 7 (08) :831-U93

[3]

Roscovitine targets, protein kinases and pyridoxal kinase [J].

Bach, S ;

Knockaert, M ;

Reinhardt, J ;

Lozach, O ;

Schmitt, S ;

Baratte, B ;

Koken, M ;

Coburn, SP ;

Tang, L ;

Jiang, T ;

Liang, DC ;

Galons, H ;

Dierick, JF ;

Pinna, LA ;

Meggio, F ;

Totzke, F ;

Schächtele, C ;

Lerman, AS ;

Carnero, A ;

Wan, YQ ;

Gray, N ;

Meijer, L .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (35) :31208-31219

[4]

Cdk2 knockout mice are viable [J].

Berthet, C ;

Aleem, E ;

Coppola, V ;

Tessarollo, L ;

Kaldis, P .

CURRENT BIOLOGY, 2003, 13 (20) :1775-1785

[5]

Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases [J].

Bettayeb, Karima ;

Tirado, Oscar M. ;

Marionneau-Lambot, Severine ;

Ferandin, Yoan ;

Lozach, Olivier ;

Morris, Jonathan C. ;

Mateo-Lozano, Silvia ;

Drueckes, Peter ;

Schaechtele, Christoph ;

Kubbutat, Michael H. G. ;

Liger, Francois ;

Marquet, Bernard ;

Joseph, Benoit ;

Echalier, Aude ;

Endicott, Jane A. ;

Notario, Vicente ;

Meijer, Laurent .

CANCER RESEARCH, 2007, 67 (17) :8325-8334

[6]

Deregulated degradation of the cdk inhibitor p27 and malignant transformation [J].

Bloom, J ;

Pagano, M .

SEMINARS IN CANCER BIOLOGY, 2003, 13 (01) :41-47

[7]

Protein kinases - the major drug targets of the twenty-first century? [J].

Cohen, P .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315

[8]

New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? [J].

Coqueret, O .

TRENDS IN CELL BIOLOGY, 2003, 13 (02) :65-70

[9]

A Jekyll and Hyde disease: roles for Cdk5 in brain development and disease [J].

Cruz, JC ;

Tsai, LH .

CURRENT OPINION IN NEUROBIOLOGY, 2004, 14 (03) :390-394

[10]

Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate [J].

Davies, TG ;

Tunnah, P ;

Meijer, L ;

Marko, D ;

Eisenbrand, G ;

Endicott, JA ;

Noble, MEM .

STRUCTURE, 2001, 9 (05) :389-397

← 1 2 3 4 5 →